-
Safety and pharmacokinetics of anti-inflammatory NE3107 treatment in carbidopa/levodopa-treated patients with Parkinson’s disease: A phase 2a, double-blind, placebo-controlled study
-
Safety assessment of pimavanserin in Parkinson’s disease psychosis patients: Evidence from a systematic review and meta-analysis of randomized controlled trials
-
Safety in Levodopa/carbidopa Intestinal Gel (LCGI) titration in the Intensive Care Unit (ICU) setting for Parkinson’s Disease (PD) patient with severe dysphagia
-
Safety of foslevodopa/foscarbidopa during optimization and maintenance treatment: Post hoc analysis of a phase 3, single-arm trial
-
Safety profile of pimavanserin therapy in elderly patients with neurodegenerative disease-related neuropsychiatric symptoms: a Phase 3b study
-
Safinamide in Parkinson´s Disease. A retrospective study
-
Salivary α-synuclein in Parkinson’s disease – a pilot study
-
SARS-CoV-2 infection exacerbates the cellular pathology in Parkinson’s disease progression
-
Screening and Treatment of Depression in Parkinson’s Disease Within Movement Disorders Centers
-
Screening risk of falls in Parkinson’s disease population living in underserved areas
- « Previous Page
- 1
- …
- 148
- 149
- 150
- 151
- 152
- …
- 186
- Next Page »